Cetera Investment Advisers increased its stake in shares of Abrdn Life Sciences Investors (NYSE:HQL – Free Report) by 6.9% in the second quarter, Holdings Channel reports. The firm owned 156,384 shares of the company’s stock after buying an additional 10,137 shares during the quarter. Cetera Investment Advisers’ holdings in Abrdn Life Sciences Investors were worth $2,216,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Future Financial Wealth Managment LLC bought a new position in Abrdn Life Sciences Investors during the first quarter worth about $27,000. B. Riley Wealth Advisors Inc. bought a new stake in shares of Abrdn Life Sciences Investors in the 1st quarter valued at about $143,000. Wedbush Securities Inc. raised its position in shares of Abrdn Life Sciences Investors by 8.2% in the 2nd quarter. Wedbush Securities Inc. now owns 16,673 shares of the company’s stock valued at $236,000 after acquiring an additional 1,261 shares during the period. Oppenheimer & Co. Inc. boosted its stake in Abrdn Life Sciences Investors by 4.6% during the 1st quarter. Oppenheimer & Co. Inc. now owns 18,414 shares of the company’s stock worth $251,000 after acquiring an additional 814 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Abrdn Life Sciences Investors by 2.6% during the second quarter. Commonwealth Equity Services LLC now owns 33,788 shares of the company’s stock valued at $479,000 after purchasing an additional 868 shares during the period. 32.21% of the stock is owned by institutional investors and hedge funds.
Abrdn Life Sciences Investors Stock Up 0.1 %
Shares of NYSE:HQL opened at $14.85 on Friday. The company has a 50 day moving average price of $15.15 and a two-hundred day moving average price of $14.35. Abrdn Life Sciences Investors has a 52 week low of $11.34 and a 52 week high of $15.90.
Abrdn Life Sciences Investors Increases Dividend
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
Featured Articles
- Five stocks we like better than Abrdn Life Sciences Investors
- What Makes a Stock a Good Dividend Stock?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- Financial Services Stocks Investing
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- The Significance of Brokerage Rankings in Stock Selection
- MarketBeat Week in Review – 10/7 – 10/11
Want to see what other hedge funds are holding HQL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abrdn Life Sciences Investors (NYSE:HQL – Free Report).
Receive News & Ratings for Abrdn Life Sciences Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abrdn Life Sciences Investors and related companies with MarketBeat.com's FREE daily email newsletter.